Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma-Reference-Cited by-同舟云学术

Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma

Published:2019-01 Issue:1 Volume:93 Page:33-40
ISSN:0923-1811
Container-title:Journal of Dermatological Science
language:en
Short-container-title:Journal of Dermatological Science

Author:

Kubo Yosuke,Fukushima Satoshi,Inamori Yukiko,Tsuruta Mina,Egashira Sho,Yamada-Kanazawa Saori,Nakahara Satoshi,Tokuzumi Aki,Miyashita Azusa,Aoi Jun,Kajihara Ikko,Tomita Yusuke,Wakamatsu Kazumasa,Jinnin Masatoshi,Ihn Hironobu

Funder

JSPS Grant

Publisher

Elsevier BV

Subject

Dermatology,Molecular Biology,Biochemistry

Reference25 articles.

1. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N. Engl. J. Med.,2012

2. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N. Engl. J. Med.,2015

3. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab;Topalian;J. Clin. Oncol.,2014

4. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N. Engl. J. Med.,2015

5. Pembrolizumab for treatment of patients with advanced or unresectable melanoma;Sullivan;Clin. Cancer Res.,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Analysis of Immune Responses to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer;Annals of Surgical Oncology;2024-08-27

2. Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy;Supportive Care in Cancer;2024-05-22

3. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?;Pharmacology & Therapeutics;2024-04

4. Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy;2024-02-22

5. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer;Targeted Oncology;2024-01